Market revenue in 2023 | USD 1.3 million |
Market revenue in 2030 | USD 19.6 million |
Growth rate | 48% (CAGR from 2023 to 2030) |
Largest segment | C.difficle |
Fastest growing segment | C.difficle |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | C.difficle, Crohns disease, IBS, Diabetes |
Key market players worldwide | Carbios SA, Boise Cascade Co, Assembly Biosciences Inc, Wacker Chemie AG, SGS AG, Lonza Group Ltd, Arranta Bio, 4D Pharma, NIZO, Inpac Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to live biotherapeutic products and microbiome cdmo market will help companies and investors design strategic landscapes.
C.difficle was the largest segment with a revenue share of 84.62% in 2023. Horizon Databook has segmented the Germany live biotherapeutic products and microbiome cdmo market based on c.difficle, crohns disease, ibs, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
In Germany, the rapidly aging population, growing demand for biotherapeutics, and emerging chronic diseases have increased the pressure on pharmaceutical companies to innovate new drugs for patients.
These factors have led pharmaceutical and biotechnology companies to shift their focus on R&D for the production of niche live biotherapeutic products and microbiomes. Furthermore, growing hospital-acquired CDIs have led to a rise in demand for management of CDIs and Recurrent CDIs (rCDIs).
This resistant C. difficile colonizes the intestines, leading to infectious diarrhea and colitis. Hence, different guidelines have introduced non-antibiotic options for the treatment of rCDI; for instance, Merck & Co., Inc.'s Zinplava is a monoclonal antibody against the C. difficile toxin.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany live biotherapeutic products and microbiome cdmo market , including forecasts for subscribers. This country databook contains high-level insights into Germany live biotherapeutic products and microbiome cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account